Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

CorAlert

CorAlert_logo
4
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Misgav, Misgav, Israel

Send a message

Anglais

CorAlert

Anglais

Non-Invasive Real-Time Hemodynamic monitor for the management of Hear Failure (LVEDP)

Heart failure (HF) affects more than 26 million people globally. More than 40% of persons diagnosed with HF will die within 5 years. HF accounts for nearly $30 billion in medical expenses yearly.

A major contributor to HF’s high mortality rate and cost of treatment is the difficulty in assessing the condition of the heart in real-time.

Left...

See more

Non-Invasive Real-Time Hemodynamic monitor for the management of Hear Failure (LVEDP)

Heart failure (HF) affects more than 26 million people globally. More than 40% of persons diagnosed with HF will die within 5 years. HF accounts for nearly $30 billion in medical expenses yearly.

A major contributor to HF’s high mortality rate and cost of treatment is the difficulty in assessing the condition of the heart in real-time.

Left ventricular end-diastolic pressure (LVEDP), the left ventricle’s filling pressure, is an accepted index to assess the severity of HF. 

CORALERT’S UNIQUE SOLUTION

CorAlert has developed an accurate, easy-to-use, noninvasive device for measuring LVEDP in real-time. Our device accurately estimates LVEDP along with other vital hemodynamic indices. The device supplies the physician a comprehensive hemodynamic profile allowing to accurately determine the exact type and severity of heart failure, and along with the cloud application allows for long term trend analysis and prediction of the patient prognosis.

CURRENT STATUS

CorAlert is conducting a clinical trial validating the accuracy of the device (Ziv Medical Center, Israel). The trial compares LVEDP measured in the Cath lab during routine elective catheterization to the LVEDP measured by CorAlert’s device. Correlation coefficient of the 2 measurements currently stands at >0.9 with p value <0.00013.

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1145 Entities

Communities